Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported purchases exceed sales by $29.4MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management Llc | Director | Jul 16 '26 | Buy | $14.50 | 853,450 | $12,375,025 | 3,601,316 | Jul 20 05:30 PM |
| Lynch Ryan | See Remarks | Jun 22 '26 | Sale | $17.99 | 465 | $8,365 | 13,871 | Jun 23 04:04 PM |
| Pinkas Jan | Chief Scientific Officer | Jun 22 '26 | Sale | $17.99 | 1,288 | $23,171 | 22,239 | Jun 23 04:04 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.